Patients with MS stable on natalizumab administered every 4 weeks may be able to safely switch to every-6-weeks dosing with no clinically meaningful loss of efficacy.
A study of all MS patients in England taking a disease modifying therapy found higher infection and hospitalization rates in patients taking those drugs, even after COVID-19 vaccination.
Data from NOVA study further support the efficacy and safety of natalizumab IV when administered every six weeks as compared to the approved every four-week dosingAdditional real-world data affirm high